cas 218594-79-7|| where to buy (S)-3-(Hydroxymethyl)morpholine Hydrochloride

製品名:(S)-3-(Hydroxymethyl)morpholine Hydrochloride

IUPAC Name:[(3S)-morpholin-3-yl]methanol hydrochloride

包装単位	有効在庫	価格（USD）
CM116109-1g	in stock	ƴȤ
CM116109-5g	in stock	Ȥƴǆ
CM116109-10g	in stock	Ÿœȅ
CM116109-25g	in stock	ƴƴƴ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 218594-79-7 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:218594-79-7; 分子式:C5H12ClNO2; 融点:-; SMILESコード:OC[C@@H]1NCCOC1.[H]Cl; 密度:

: カタログ番号:CM116109; 分子量:153.61; 沸点:; MDL番号:MFCD12547468; 保管方法:Store at 2-8°C.

: Morpholines; Morpholine contains secondary amine groups and has all the typical reactive characteristics of secondary amine groups. It can react with inorganic acids to form salts, and react with organic acids to form salts or amides, which can be subjected to alkylation reaction, and can also be reacted with ethylene oxide, ketone or Willgerodt reaction. Morpholine is a six-membered ring containing oxygen and nitrogen, and its alkalinity is much lower than that of its parent piperidine. The marketed morpholine drugs are mainly distributed in the fields of tumors, cardiovascular and cerebrovascular diseases, respiratory system diseases, digestive system diseases, infectious diseases and mental disorders.; morpholine price; if you are interested in morpholine price, please feel free to contact us. More information of our products will be forwarded to you upon receipt of your specific inquiry.

: Elinzanetant; On January 8, 2024, Bayer announced positive top-line results of the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo. Elinzanetant successfully met all four primary endpoints and all three key secondary endpoints in both studies. Elinzanetant is a first dual neurokinin-1,3 (NK-1,3) receptor antagonist for the non-hormonal treatment of moderate to severe VMS associated with menopause. Elinzanetant may address moderate to severe VMS by modulating a group of estrogen sensitive neurons in the hypothalamus region of the brain (the KNDy neurons) which, with the decrease of estrogen, become hypertrophic and lead to a hyperactivation of the thermoregulatory pathway, consequently disrupting body heat control mechanisms resulting in VMS. Elinzanetant may also decrease sleep disturbances associated with menopause.